2024-12-10
Grand Life Sciences and Cali Biosciences Announce Strategic Collaboration for CPL-01 Commercialization
Potentially Pioneering a New Era in Peri-Operative Pain Management
Accelerating Commercialization of CPL-01 in China
Beijing and San Diego, December 2, 2024 Grand Life Sciences Group Co., Ltd. (“Grand Life Sciences”), an integrated pharmaceutical company with full value chain capacities and a global vision, and...
2024-05-21
SAN DIEGO, May 20, 2024 -- Cali Biosciences Co., Ltd. (hereinafter referred to as “Cali Biosciences”), a biotechnology company dedicated to the research and development of innovative drugs, announced publication of “CPL‑01, an investigational long‑acting ropivacaine, demonstrates safety and efficacy in open inguinal hernia repair” in the scientific journal Hernia. The article’s authors are Hanghang Tommy Xu, John ...
2023-06-06
Subjects in Bunionectomy Study Dosed
Data Presented at American Society for Pharmacology and Experimental Therapeutics Shows Similar Ropivacaine Pharmacokinetic Curves From CPL-01 Across Multiple Surgeries; Minimal Variability as Compared to Liposomal Bupivacaine
SAN DIEGO, June 6, 2023 /PRNewswire/ -- Cali Biosciences Co., Ltd. (hereinafter referred to as "Cali" or "Cali Biosciences"),...
2023-05-26
- Subjects in Herniorrhaphy Study Dosed
- Successful FDA Interactions on Two Pre-clinical Pipeline Products Also Discussed
SAN DIEGO, April 18, 2023 /PRNewswire/ -- Cali Biosciences Co., Ltd. (hereinafter referred to as "Cali" or "Cali Biosciences"), a biopharmaceutical company focused on the research and development of innovative drugs in the peri-operative space, announced it has initiated ...
2022-10-17
Cali Biosciences Co., Ltd. (hereinafter referred to as "Cali Biosciences"), a biopharmaceutical company focused on the research and development of innovative drugs, announced two major milestones for CPL-01, its long-acting ropivacaine for post-operative analgesia and opioid elimination/reduction:
Publication of “CPL-01, an Investigational Long-Acting Ropivacaine, Exhibits Extended-Release Properties after Mini-abdominoplasty” i...
2022-07-27
Cali Biosciences Co., Ltd. (hereinafter referred to as "CaliBio"), a global biopharmaceutical company focused on the research and development of innovative drugs, announced it has initiated a Phase II bunionectomy study of its peri-operative long-acting ropivacaine product (CPL- 01) for post-operative pain control and opioid reduction through 72 hours after bunionectomy. In a surprise, all slots in the initial cohort of the trial immediat...
2022-03-21
SAN DIEGO, March 21, 2022 /PRNewswire/ -- Cali Biosciences Co., Ltd. (hereinafter referred to as "Cali Biosciences"), a biopharmaceutical company focused on the research and development of innovative drugs, announced successful results in its Phase IIb study of its perioperative long-acting analgesic product CPL-01.
CPL-01 is an extended-release injectable version of Naropin® (ropivacaine hydrochloride), deve...
2021-11-19
SAN DIEGO, Nov. 19, 2021 /PRNewswire/ -- Cali Biosciences, a global biopharmaceutical company focused on the research and development of innovative drugs, presented Phase IIa clinical data today on its perioperative long-acting ropivacaine, CPL- 01, at the 20th Annual American Society of Regional Anesthesia and Pain Medicine (ASRA) Meeting.
CPL-01 is an extended-release injectable version of ropivacaine hydroc...
2021-08-11
SAN DIEGO, Aug. 11, 2021 /PRNewswire/ -- Cali Biosciences Co., Ltd. (hereinafter referred to as "CaliBio"), a global biopharmaceutical company focused on the research and development of innovative drugs, announced it has initiated a Phase 2b study of its perioperative long-acting analgesic product CPL- 01.
CPL-01 is an extended-release injectable version of Naropin® (ropivacaine hydrochloride), developed by CaliBio to treat...